FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to new derivatives of benzothiadiazoles, benzoxadiazoles and benzodiazines of the formula (I) 
as free base form or pharmaceutically acceptable acid-additive salt. These compounds can be used as an anxiolytic agent in treatment of any state that is associated with enhanced CRF level or when regulation of HPA is damaged (system hypothalamus-hypophysis), in different diseases that are caused by CRF1 or manifestation of that CRF1 promotes, such as arthritis, asthma, allergy, anxiety state, depression and so on. In compounds of the formula (I) X means oxygen, sulfur atom or CH=CH; R1 and R2 mean independently each of other hydrogen, halogen atom or C1-C4-alkyl; Het means radical of one of below given formulas: (a), (c), (e), (m) wherein 
and 
mean independently each of other 
-alkyl; 
means hydrogen, halogen atom, R3/ -alkyl or cyano-group; R8 and C1-C4 mean independently each of other hydrogen atom, R4-alkyl, C1-C4-alkenyl, R5-cycloalkyl, R6-cycloalkyl-C1-C7-alkyl, C3-C7-alkoxy-C3-C7-alkyl or benzyl; C3-C7 means C1-C4-alkyl; W means nitrogen atom. Invention relates also to method for preparing compounds by interaction of compound of the formula (II) C1-C4 wherein X, C2-C5 have values indicated in cl. 1; Y means radical of one of below given formulas: (a'), (c'), (e'), (m') wherein R7 and W have values indicated above; Hal means halogen atom with compound of the formula (III): C1-C4 wherein 
values indicated above and isolation of compound of the formula (I) prepared by indicated way as free base form or acid-additive salt form. Pharmaceutical composition comprises compound of the formula (I) as free base form or acid- -additive salt form in combination with pharmaceutical carrier or excipient. EFFECT: improved preparing method, valuable medicinal properties of compounds. 6 cl, 1 ex R1, R2
R3-R8 HN(R5)(R6) R5, R6
| Title | Year | Author | Number |
|---|---|---|---|
| QUINAZOLINONE DERIVATIVES AND THEIR USE AS AGONISTS OF CANNABINOID (CB) RECEPTOR | 2003 |
|
RU2374235C2 |
| (-AMINO-(-HYDROXY-(-ARYLALKANOIC AMIDES AND USE THEREOF AS RENIN INHIBITORS | 2004 |
|
RU2425027C2 |
| PYRROLIDINIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS | 2005 |
|
RU2412183C2 |
| PREPARING STERIC HINDERED AMINE ETHERS | 1999 |
|
RU2224758C2 |
| COMPOUNDS FOR TREATING COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2703995C2 |
| HIV-INHIBITING 5-CARBO- OR HETEROCYCLIC SUBSTITUTED PYRIMIDINES | 2005 |
|
RU2403244C2 |
| SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | 2011 |
|
RU2603637C2 |
| THIOPYRIDINES USED FOR CONTROL OF HELICOBACTER BACTERIA | 1995 |
|
RU2142459C1 |
| METHOD FOR (CO) | 2001 |
|
RU2273649C2 |
| PYRIMIDINE DERIVATIVES | 2003 |
|
RU2324684C2 |
